/PRNewswire/ Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve.
In a systematic review and meta-analysis, Tao Lin and colleagues investigate the incidence, risk factors and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection.
- Study recommends a simplified strategy for baseline testing and minimal monitoring for treatment of hepatitis C virus (HCV) infection with DAA Therapies - Review of implementation science projects toward HCV Elimination by 2030 in Asia proved effective in improving patient outcomes - Efficacy and safety demonstrated with Bictegravir/Emtricitabine/Tenofovir Alafenamide as compared to Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate as initial treatment in HIV-1/HBV-Coinfected adults SINGAPORE, Feb. 15, 2023 /PRNewswire/ Gilead Sciences Inc. today announced data from multiple studies highlighting the urgency for increased screening, the need for a simplified treatment strategy for Hepatitis C (HCV) infection in the Asia region, and the efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1/HBV-coinfected adults. The data will be presented at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2023), to be held 15 -
2023 Australia Day Awards: The Jewish Recipients – J-Wire jwire.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jwire.com.au Daily Mail and Mail on Sunday newspapers.